Venture Life Group manages a growing portfolio of non-prescription healthcare brands focused on ageing consumers, supported by its integrated product development and manufacturing model. The shares trade on a low multiple, particularly given that VLG will report positive EBITDA in 2016, has revenue momentum and prospects of near term, self-sustaining profitability.
